VIR Stock Analysis: Buy, Sell, or Hold?
VIR - Vir Biotechnology, Inc. Common Stock
$10.16
0.59 (6.17%)
▲
5d:
+18.0%
30d:
+12.51%
90d:
+14.93%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When VIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: VIR is 8.2% above its trading range ($9.39). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: VIR is 8.2% above its trading range ($9.39). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: VIR is currently trading at $10.16, which is considered extended relative to its 30-day fair value range of $8.52 to $9.39.
Technical Outlook: Technically, VIR is in a downtrend. The price is approaching resistance at $10.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: VIR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.56 (+112.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VIR is in a downtrend. The price is approaching resistance at $10.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: VIR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.56 (+112.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.52 -
$9.39
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.2%)
- BULLISH: Trading 112.2% below Wall St target ($21.56)
- CAUTION: Extended 8.2% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$8.52 -
$9.39
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.16
Resistance Level
$10.18
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.37
Wall Street Target
$21.56
(+112.2%)
Revenue Growth (YoY)
417.8%
Earnings Growth (YoY)
58.5%
Share & Embed Analysis
Last updated: June 23, 2026 6:03 PM ET
Data refreshes hourly during market hours. Next update: 7:03 PM
Data refreshes hourly during market hours. Next update: 7:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Backer Marianne De
SELL
72559 shares
2026-04-06
Vicki L Sato
SELL
22000 shares
2026-04-01
Brent Sabatini
SELL
7711 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 63 BUY |
